PERNIX THERAPEUTICS HOLDINGS, INC.

Form 8-K November 12, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2013

PERNIX THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Maryland	001-14494	33-0724736
(State or other	(Commission File	(IRS Employer
jurisdiction	Number)	Identification No.)
of incorporation)		
10863 Rockley Road		
•	77099	
Houston, Texas	77099	
(Address of principal	(Zip Code)	
executive offices)		

Registrant's telephone number, including area code: (832) 934-1825

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PERNIX THERAPEUTICS HOLDINGS, INC. - Form 8-K

Item 2.02

Results of Operations and Financial Condition

On November 12, 2013, Pernix Therapeutics Holdings, Inc. (the "Company") issued a press release reporting its results for the third quarter ended September 30, 2013. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 2.02 (and in Item 9.01) shall be deemed to be furnished to the Securities and Exchange Commission but not filed, and shall not be deemed to be incorporated by reference into any filings by the Company under the Securities Act of 1933, as amended, unless the Company expressly states otherwise in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit

Number Description

99.1 Press release by Pernix Therapeutics Holdings, Inc. dated November 12,

2013 reporting its results for the third quarter ended September 30, 2013

Edgar Filing: PERNIX THERAPEUTICS HOLDINGS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PERNIX THERAPEUTICS HOLDINGS, INC.

By: /s/ Tracy Clifford

Tracy Clifford

Principal Financial and Accounting

Officer

Dated: November 12, 2013